Estradiol Patch and Testosterone Interaction: What Patients and Clinicians Need to Know

Does the estradiol patch interact with testosterone?

The patch labels do not mention testosterone in their drug interactions sections. For Climara, that section covers one enzyme family: CYP3A4 inducers such as St. John's wort, phenobarbital, carbamazepine and rifampin may lower estrogen concentrations, and inhibitors such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may raise them [1]. Vivelle-Dot carries the same section [6].

The testosterone side is equally narrow. The Depo-Testosterone (testosterone cypionate) label says androgens may increase sensitivity to oral anticoagulants and the anticoagulant dose may need to be reduced, that oxyphenbutazone levels may rise with concurrent use, and that in diabetes androgens may lower blood glucose and insulin requirements [2]. The testosterone enanthate label adds that androgens given with corticosteroids or ACTH may increase fluid retention [7]. Neither interactions section names estradiol.

The contraindications sections do not name the other drug either. Climara is contraindicated in undiagnosed abnormal genital bleeding, breast cancer or its history, estrogen-dependent neoplasia, active or prior DVT or PE, active or prior arterial thromboembolic disease, hypersensitivity, hepatic impairment or disease, and thrombophilic disorders [1]. Depo-Testosterone is contraindicated in hypersensitivity, men with breast cancer, men with known or suspected prostate cancer, women who are pregnant, and patients with serious cardiac, hepatic or renal disease [2].

Testosterone already produces estradiol

Aromatase converts androgens to estrogens, and it is expressed in Leydig cells and other tissues [5]. Someone using testosterone therefore already has some circulating estradiol made from it, and an estradiol patch adds exogenous estradiol on top of that. This describes hormone exposure, not a measured interaction.

Blood pressure

After reviewing ambulatory blood pressure monitoring studies, FDA reported in February 2025 that a blood pressure increase was confirmed with all testosterone products, class-wide, and required a new blood pressure warning for products that did not already have one [3]. The Depo-Testosterone label states that testosterone can increase blood pressure, which can increase cardiovascular risk over time, that blood pressure should be monitored periodically, and that these products are not recommended in uncontrolled hypertension [2].

On the patch side, the Climara label lists changes in blood pressure among postmarketing reports, in a voluntary-reporting list where a causal relationship cannot be established [1]. That is a weaker signal than the testosterone data.

Hematocrit and red blood cells

Testosterone's effect on red cell mass is the best documented of these overlaps. The Depo-Testosterone label calls for hemoglobin and hematocrit to be checked periodically during long-term use [2]. A network meta-analysis of 29 placebo-controlled randomized trials in 3,393 men found every testosterone formulation raised mean hematocrit versus placebo: intramuscular enanthate and cypionate by 4.0% (95% CI 2.9 to 5.1), oral testosterone undecanoate by 4.3%, gel by 3.0%, testosterone patch by 1.4%, and intramuscular undecanoate by 1.6% [4]. Of the comparisons between formulations, only intramuscular enanthate/cypionate versus the testosterone patch differed significantly [4].

A retrospective review of 178 hypogonadal men followed for 3 years found hematocrit above 50% in 66.7% of those on injectable testosterone versus 12.8% on gels and 35.1% on pellets; the injection group was younger (mean 42.5 versus about 54 years) with higher baseline hematocrit, and the review was not randomized [8].

Free testosterone and binding protein

The Depo-Testosterone label states that about 98% of plasma testosterone is bound to a testosterone-estradiol binding globulin and about 2% is free, and that the amount of this globulin in plasma determines how testosterone divides between bound and free forms [2]. The label does not say whether an estradiol patch changes that balance, and the patch labels do not report an effect on testosterone binding [1][6].

Clot risk

This is where the patch label draws its hardest line. Climara is contraindicated in women with active DVT or PE or a history of either, and in those with active arterial thromboembolic disease or a history of it [1]. Its boxed warning reports increased stroke and DVT with estrogen alone in the Women's Health Initiative and states that only daily oral conjugated estrogens 0.625 mg were studied, so the relevance of those findings to other routes of administration is not known [1].

Observational data point toward transdermal estrogen carrying less clot risk than oral. In the ESTHER case-control study, 271 women with a first idiopathic VTE and 610 matched controls gave an adjusted odds ratio of 4.2 (95% CI 1.5 to 11.6) for oral estrogen and 0.9 (0.4 to 2.1) for transdermal, compared with non-users [9]. In the observational studies pooled by the BMJ review, the odds ratios for a first clot were 2.5 (1.9 to 3.4) with oral estrogen and 1.2 (0.9 to 1.7) with transdermal estrogen, compared with nonusers [10]. Neither is randomized evidence about the patch, and the label's contraindications stand regardless.

On the testosterone side, the Depo-Testosterone label reports postmarketing deep vein thrombosis and pulmonary embolism with testosterone products, says to evaluate leg pain, edema, warmth and erythema for DVT and acute shortness of breath for PE, and says to discontinue treatment if an event is suspected [2]. Venous thromboembolism appears among its listed adverse reactions [2].

Who the testosterone labels cover

Depo-Testosterone is labeled for replacement therapy in males with primary or hypogonadotropic hypogonadism [2]. FDA states that approved testosterone products are for men who have low testosterone together with an associated medical condition [11]. The testosterone enanthate label also lists metastatic breast cancer in postmenopausal women as a secondary indication [7].

Bottom line

At the label level, neither product's interactions section lists the other drug, and how the combination affects drug levels has not been established [1][6][2]. The shared concerns the labels and studies do document are blood pressure and hematocrit on the testosterone side, and clot history and unexplained genital bleeding on the estrogen side [1][2][3][4].